Peter is an experienced life science industry consultant and leads the firm’s initiatives in translational medicine. He is the Program Manager for the Wake Forest Technology Development Program and also provides business development and due diligence support to the firm’s venture funds and portfolio companies. Peter joined Pappas Capital in 2012, serving initially as an Executive-in-Residence and currently as a Venture Partner.
Peter has 40 years of experience in the pharmaceutical and biotechnology industry, spanning all areas of the business from sales representative to country-level general manager and CEO; and companies ranging from multinationals like Abbott and Glaxo to start-up biotechnology companies. As Vice President and Therapy Area Head at Glaxo Wellcome in the mid-1990s, he led the global introduction of combination HIV therapy that revolutionized HIV treatment and quintupled Glaxo’s global HIV portfolio sales, while keying industry leadership on global treatment access. Peter has since served as CEO of two private start-up enterprises, a viral vector vaccine company that raised over $80 million in NIH HIV and biodefense vaccine grants, and a specialty pharmaceutical company he led to an exit via a strategic transaction.
Peter currently serves on the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research, and is a member of the Long Island Bioscience Hub External Review Board. He is also an Executive-in-Residence at Cold Spring Harbor Laboratory and the Stony Brook University Center for Biotechnology, and also serves as a Mentor-in-Residence at Rutgers University. Peter was a past member of the BIO board, past Chairman of the North Carolina Biosciences Organization (NCBIO), and was a director of Memory Pharmaceuticals from 2004 until its sale to Roche in 2009. He has lived and worked in the US, Greece, the Middle East, Puerto Rico, New Zealand and London.
Indiana University (BA, History)
IU Kelley School of Business (MBA)
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.